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Resistance to 157 different herbicides and 88% of known sites of action has been observed, with 
many weeds resistant to two or more modes. Coupled with tighter environmental regulation, this 
demonstrates the need to identify new modes of action and novel herbicides. The plant sphingolipid 
biosynthetic enzyme, inositol phosphorylceramide synthase (IPCS), has been identified as a novel, 
putative herbicide target. The non-mammalian nature of this enzyme offers the potential of discovering 
plant specific inhibitory compounds with minimal impact on animals and humans, perhaps leading 
to the development of new non-toxic herbicides. The best characterised and most highly expressed 
isoform of the enzyme in the model-dicot Arabidopsis, AtIPCS2, was formatted into a yeast-based assay 
which was then utilized to screen a proprietary library of over 11,000 compounds provided by Bayer 
AG. Hits from this screen were validated in a secondary in vitro enzyme assay. These studies led to the 
identification of a potent inhibitor that showed selectivity for AtIPCS2 over the yeast orthologue, and 
activity against Arabidopsis seedlings. This work highlighted the use of a yeast-based screening assay to 
discover herbicidal compounds and the status of the plant IPCS as a novel herbicidal target.
First discovered in Saccharomyces cerevisiae, inositol phosphorylceramide synthase (IPCS or Aur1p in yeast) 
catalyses the transfer of phosphorylinositol from the phosphoglycerolipid phosphatidylinositol to the C-1 
hydroxyl group of (phyto)ceramide, thereby generating the complex sphingolipid inositol phosphorylceramide 
(IPC)1. IPC is subsequently a precursor for the generation of the other, more complex, sphingolipids: mannosylin-
ositol phosphorylceramide (MIPC) and mannosyldiinositol phosphorylceramide [M(IP)2C]2. These have been 
shown to be vital for the localization and endocytosis of plasma membrane proteins in S. pombe3. In addition, 
aside from maintaining the structural integrity of the plasma membrane, sphingolipids have been demonstrated 
to play crucial roles in a number of eukaryotic cell processes including apoptosis4,5, cell differentiation6, cell cycle 
arrest7, cell signalling8, angiogenesis9 and senescence10.
The sphingolipid biosynthetic pathway, and the enzymes involved, show conservation in all kingdoms of the 
Eukaryota up to the formation of dihydrosphingosine11. Subsequently there is divergence, dihydrosphingosine is 
N-acylated to produce dihydroceramide which is then desaturated to give ceramide in mammals and protozoa. 
In contrast, in plants and fungi, phytosphingosine, generated from the hydroxylation of dihydrosphingosine, is 
N-acylated to give phytoceramide. Subsequently, these intermediary metabolites are transported into the Golgi 
apparatus where sphingomyelin synthase catalyzes the production of sphingomyelin, the major sphingolipid in 
mammals, and IPCS generates IPC in plants, fungi and protozoa11.
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This divergence in sphingolipid biosynthesis has been exploited to investigate the protozoal IPCS as a thera-
peutic target for the Neglected Tropical Diseases, Chagas disease12–14 and leishmaniais15–18. In plants, the activity 
of IPCS was first characterized in Phaseolus vulgaris19 and its role as a negative regulator of programmed cell 
death in plants was validated in Arabidopsis thaliana20 and Eucalyptus grandis21. In Oryza sativa, IPCS has been 
shown to play a role in plant response to abiotic stress, particularly in response to drought, cold and salinity22.
Despite the fact that hundreds of herbicides are widely used, these only exhibit 25 modes of action. In fact, 
merely 6 modes of action, targeting 5-enolpyruvylshikimate-3-phosphate (EPSP) synthase, acetolactate synthase 
(ALS), photosystem (PS) II, synthetic auxins, acetyl CoA carboxylase (ACCase) and cell division, acount for 75% 
of the herbicide market23. It has been over 30 years since a herbicide with a new mode of action was introduced 
onto the market and, with the growing problem of herbicide resistance24 and the destabilizing effect of climate 
change on crop yield25, it is now necessary to identify new herbicidal modalities to ameliorate the challenge of 
feeding a rapidly increasing global population set to reach 9–10 billion in 205026.
As previously reported20–22, inhibition of the plant IPCS would lead to a buildup of the enzyme substrate, 
the Programmed Cell Death (PCD; apoptosis) mediator phytoceramide27. The functional divergence of IPCS 
from the equivalent mammalian enzyme, sphingomyelin synthase (SMS), could allow the identification of spe-
cific, non-toxic inhibitors. This possibility has, to date, lead to the identification of 5 potent inhibitors of the 
fungal IPCS (aureobasidin A28 (AbA), khafrefungin29, rustimicin30, pleofungin31 and haplofungin32) with low 
nano-molar IC50 values against Saccharomyces cerevisiae. However, currently, no inhibitor of the plant orthologue 
has been identified.
In this study, the well characterized Arabidopsis thaliana enzyme AtIPCS220, the most highly expressed of 
the 3 IPCS isoforms33, was used to complement S. cerevisiae lacking AUR1. The yeast utilized was engineered to 
enhance compound sensitivity through reduced expression of several efflux pumps, and thereby allow efficient 
hit identification in a cell-based high throughput screening (HTS) assay used for 11,440 bioactive compounds. 
A secondary enzyme-based assay facilitated the validation of hits as inhibitors of the enzyme, and enabled com-
parison of their activity against the yeast orthologue, Aur1p. This allowed the identification of hits that exhibited 
selectivity for IPCS2 from A. thaliana. The most potent selective compound was tested in vivo against seedlings 
and demonstrated herbicidal activity.
Results
Primary high throughput screening using a yeast-based assay. Fungi such as Saccharomyces cer-
evisiae possess multiple genes linked to pleiotropic drug resistance, including those encoding a range of ATP-
binding cassette (ABC) transporters and the transcription factors required for their expression34. These extrusion 
pumps can be over-expressed in response to drug treatment, leading to decreased intracellular drug concentra-
tions and subsequent drug resistance35, while multiple deletions of these functions render yeast cells significantly 
more sensitive to a range of toxic compounds including antifungal agents used in agriculture and medicine8. To 
increase the sensitivity of the yeast-based assay platform, an S. cerevisiae strain was utilised that lacked PDR1, 
PDR3, PDR16 and PDR17. This combination of pdr deletions was shown to confer significant hypersensitivity to 
a range of compounds (Supplementary Information 1). PDR136 and PDR337 encode paralogous Zn(II)2Cys6 zinc 
finger regulators, which control the transcription of ABC drug efflux pump-encoding genes including PDR538,39, 
SNQ240, PDR1041, PDR1541 and YOR142 through binding to cis-acting PDREs (pleiotropic drug resistance ele-
ments)40,41,43,44. PDR16 and PDR17 encode a pair of paralogous phosphatidylinositol transport proteins that also 
confer drug hypersensitivity when deleted45.
In the quadruple pdr1∆ pdr3∆ pdr16∆ pdr17∆ strain, AUR1 was deleted and replaced by a HIS3 selectable 
marker, with growth supported by expression of the essential AUR1 gene from the plasmid pRS316-AUR1 under 
uracil selection. In this background, galactose-inducible expression of AtIPCS2 from plasmid pESC-LEU was 
found to complement loss of pRS316-AUR1 when the yeast were cultured in the presence of 5-fluoroorotic acid. 
This made the yeast dependent upon the presence of galactose for growth, thus demonstrating dependence on the 
expression of the plant enzyme (Fig. 1, Supplementary Information 2)20–22. Assay of microsomal extracts from the 
complemented yeast demonstrated IPCS activity in vitro and confirmed that the plant activity is insensitive to the 
fungal Aur1p inhibitor aureobasidin A (AbA)28,33 (Fig. 2).
Yeast complemented with the well characterised AtIPCS2, and an AUR1 control, were subsequently for-
matted into a 96-well plate. Following statistical validation by calculation of Z factor46 in the presence of pos-
itive (cycloheximide) and negative (DMSO) controls, the assay was used in HTS of a focused library of 11,440 
bioactive compounds. All assay plates were required to have a calculated Z factor ≥0.5 for the data to be pro-
gressed. Following in duplicate screening at 10 µM against AtIPCS2 complemented yeast and the AUR1 control, 
Figure 1. Yeast (MSYD23) dependent on expression of AtIPCS2 from a galactose inducible promotor were, as 
expected, viable when grown in the presence of galactose (GAL), but not glucose (GLU). The relevant section of 
each agar plate (GAL and GLU) is illustrated, the full plates are shown in Supplementary Information 2.
3Scientific RepoRts |          (2019) 9:8083  | https://doi.org/10.1038/s41598-019-44544-1
www.nature.com/scientificreportswww.nature.com/scientificreports/
compounds exhibiting ≥80% inhibition and ≥50% selectivity for AtIPCS2 were taken forward. After eliminating 
false positives (non-reproducible hits; 2.6%), 106 target directed hits were identified, a hit rate of 0.9% (Fig. 3, 
Supplementary Information 3). It is notable that a significant minority of compounds increased yeast prolif-
eration and that this phenotype was more profound in the AtIPCS2 complemented yeast (negative inhibition; 
Fig. 3), whilst this is an interesting observation these were not analysed further. Dose response analyses (50 µM 
to 68 nM), using the same assay platform, demonstrated that the majority of the inhibitory compound hits (89 of 
106) had an IC50 of less than 10 µM (Supplementary Information 4).
Secondary screening using an in vitro biochemical assay. In the secondary screening stage the pre-
viously described microsomal-based in vitro IPCS assay was adapted and utilised17. Initially, all 106 selective hits 
from the primary screen were tested, in duplicate, at 10 µM. 16 compounds which, reproducibly, showed ≥30% 
inhibition were carried forward for in triplicate dose response (100 µM to 46 nM) analyses and IC50 determination 
against AtIPCS2 and, as a control, AUR1. All were active to some degree against the Arabidopsis enzyme, whilst 
none showed inhibition of the fungal orthologue, demonstrating that selective AtIPCS2 inhibitors had been iden-
tified. 4 compounds demonstrated IC50 values < 10 µM (Compound 1, 4.02 µM; 2, 4.75 µM; 3, 8.41 µM; and 4, 
9.84 µM; Supplementary Information 5). The structures of compounds 2–4 are withheld due to intellectual prop-
erty reasons, leaving the most active (Compound 1, a phenylamidine carrying an acetonitrile functional group) 
to be taken forward (Fig. 4). The structural integrity of Compound 1 was confirmed using mass spectrometry 
and 1H and 13C spectroscopy which showed that it was a 3:2 mixture of E:Z amidine isomers (see Supplementary 
Information 6).
In vivo screening. In vivo testing of the phenylamidine Compound 1 was undertaken against Arabidopsis 
seedlings grown on agar. Dose response analyses (Fig. 5) showed that treatment restricted growth and led to 
purple leaf patches at 11 µM and above. Examination of treated 7 day old seedlings grown on agar containing 10 
and 40 µM of Compound 1 showed plants with clear purple patches associated with anthocyanin biosynthesis in 
response to stress47, and an absence of lateral root development compared to the DMSO control (Fig. 6).
Discussion
With herbicide resistance increasing24 and climate change effecting on crop yield25, the need to identify new 
herbicide targets and lead molecules to address these challenges is pressing. One major hurdle to overcome in 
this search for a new herbicide is to ensure identified chemicals have acceptable toxicity profiles which are safe to 
the user and the environment48. The divergence in the sphingolipid biosynthetic pathway between mammals and 
plants, where the former produce SM and the latter IPC20,33, may present an opportunity to identify molecules 
with such a profile.
Following the recent publication of our successful HTS campaign against a protozoan IPCS49, this study is the 
first report of HTS for inhibitors of an enzyme in the plant sphingolipid synthetic pathway, the non-mammalian 
AtIPCS2 – the most highly expressed and best characterised isoform in the model dicot Arabidopsis, which catal-
yses the synthesis of IPC20,33. The role of this enzyme in phytoceramide homeostasis20,33 and therefore PCD50, cou-
pled with the product, IPC, functioning as the precursor for the synthesis of glycosylinositol phosphorylceramide 
(GIPC; 25% of plasma membrane lipid51), makes IPCS an attractive target for the discovery of new, non-toxic, 
herbicidal agents. However, given the multi-transmembrane nature of the enzyme20,33 assay development is 
Figure 2. HPTLC separation of in vitro assayed Aur1p and AtIPCS2 showing the production of NBD-IPC in 
the presence (+) and absence (−) of AbA. Only the fungal enzyme Aur1p is sensitive to the compound. NBD-
Cer is the substrate, NBD-C6-phytoceramide.
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challenging. Therefore, to facilitate HTS, we developed a novel cell-based assay utilising an AtIPCS2 comple-
mented S. cerevisiae strain lacking 4 extrusion pumps linked to pleiotropic drug resistance (PDR1, PDR3, PDR16 
and PDR17) to increase sensitivity, and utilised this system to screen a library of 11,440 bioactive compounds. 
Figure 3. Growth inhibition for compounds (10 µM) against AtIPCS2 (A) and Aur1p (B) complemented yeast. 
After eliminating false positives (2.6%), 106 target directed hits were identified, a hit rate of 0.9%.
Figure 4. Compound 1 structure and activity in the biochemical assay against AtIPCS2 and Aur1p.
Figure 5. Compound 1 tested against Arabidopsis seedlings at 3.7 µM, 11 µM, 33 µM and 100 µM. Treatment 
restricted growth and led to purple leaf patches at 11 µM and above compared to the DMSO control.
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Counter screening against Aur1p (the yeast orthologue) formatted in the same assay yielded 106 selective hits, of 
these 4 demonstrated IC50 values < 10 µM in a secondary in vitro enzyme assay and minimal activity against yeast 
Aur1p (>50 µM). The most active was a phenylamidine, Compound 1 (IC50 < 5 µM), which has been patented 
by Bayer as a fungicide52. Previous phylogenic analyses33 have shown that the three IPCS isoforms in Arabidopsis 
are closely related. Further, focused, sequence analyses demonstrated that whilst AtIPCS2 orthologues are highly 
conserved within the monocots and eudicots, there is distance between the two clades (see Supplementary 
Information 7). This indicated that selective inhibition of the enzyme (for example in a weed species) maybe 
feasible. Future studies should examine the selectivity of Compound 1 for AtIPCS2 over the other two isoforms 
and other plant orthologues to establish selectively in Planta.
The phenylamidines were first identified in the 1960s as pesticides for the control of plant fungal pathogens52 
and specific variants have subsequently been patented for use as herbicides53. In vivo screening of the identified 
phenylamidine, Compound 1, against wild type Col-0 Arabidopsis seedlings demonstrated dose dependent effects 
with decreased lateral root development, and distinctive purple leaf patches associated with anthocyanin biosyn-
thesis in response to stress47. The mode of action of herbicidal phenylamidines have not been published, but the 
phenotypic effects reported here for Compound 1 are consistent with those expected for an IPCS inhibitor.
In conclusion, using a novel HTS approach the first inhibitor (Compound 1 - a phenylamidine) of plant IPCS 
was identified and shown, in vivo, to induce the plant stress response. This low molecular weight compound 
is ideal for further development towards use in agriculture, and further studies are planned to investigate this 
possibility.
Methods
Yeast strains. The diploid Saccharomyces cerevisiae strain MSYD20 (MATa/MATα his3Δ1/his3Δ1 leu2Δ0/
leu2Δ0 MET15/met15Δ0 ura3Δ0/ura3Δ0 pdr1∆::KanMX4/pdr1∆::KanMX4 pdr3∆::KanMX4/pdr3∆::KanMX4 
pdr16∆::KanMX4/pdr16∆::KanMX4 pdr17∆::KanMX4/pdr17∆::KanMX4) is homozygous for knockouts of 
four genes conferring drug hypersensitivity and was made by sequential crosses and tetrad dissection starting 
with the single MATa pdr1∆::KanMX4 (Y04381), MATα pdr3∆::KanMX4 (Y13029), MATa pdr16∆::KanMX4 
(Y01981) and pdr17∆::KanMX4 (Y11180) strains obtained from the Euroscarf collection (http://www.euroscarf.
de). MSYD20 was made heterozygous for aur1::HIS3 (knocking out the AUR1 gene encoding yeast IPCS) by 
transformation with a PCR product amplified from pFA6a-HIS3 template using the following two primers (plas-
mid-specific sequences, upper case; AUR1 flanking sequences, lower case), generating MSYD23.
AUR1-F1
atatcctacaggttgcggttttcatattttaaaaagcttttaatcattcctttgcgtCGGATCCCCGGGTTAATTAA
AUR1-R1
atttatatgtatctacataagaccaaccgtatccgtaattgcagataaaatactcaGAATTCGAGCTCGTTTAAAC
pFA6a-HIS3 was generated by replacing the AscI-MfeI interval of pFA6a-TRP154 that carries the TRP1 gene 
with the BssHII-EcoRI fragment of YDpH55 encoding HIS3, enabling amplification of a HIS3-containing gene 
knockout fragment that cannot recombine with existing KanMX4 gene knockouts such as those present in 
MSYD20. Sporulation and tetrad analysis of MSYD23 confirmed that AUR1 is an essential gene since no viable 
aur1::HIS3 segregants could be obtained. MSYD23 was next transformed with pRS316-AUR1, made by inserting 
a copy of AUR1 into the URA3 plasmid pRS31656. Strain MSY23-3C (MATa pdr1Δ::KanMX, pdr3Δ::KanMX4 
pdr16Δ::KanMX4 pdr17Δ::KanMX4 aur1Δ::HIS3 [pRS316-AUR1]), lacking the four genes conferring drug 
hypersensitivity and in which growth was supported by AUR1 expression from pRS31615, was identified following 
sporulation and tetrad analysis of MSYD23 transformed with pRS316-AUR1. MSY23-3C was verified by appro-
priate diagnostic PCR and could not grow in the presence of 5FOA as expected.
Figure 6. From left to right, 7 day old Arabidopsis seedlings grown on agar containing DMSO (vehicle), 10 µM 
and 40 µM of Compound 1. Treated plants had clear purple patches and an absence of lateral root development 
compared to the DMSO control.
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Primary screening, yeast cell-based assay. The complete open reading frames of AtIPCS2 and 
AUR1p were amplified from cDNA or GenEZ ORF Clones (GenScript®) using Phusion Flash® PCR master mix 
(ThermoFisher) according to manufacturer’s guidelines. Primers for In-Fusion® cloning (Clontech) were:
AtIPCS2F ctcactatagggcccATGACACTTTATATTCGTCGT
AtIPCS2R tccatgtcgacgcccTCACGCGCCATTCATTGTGTT
AUR1F ctcactatagggcccATGGCAAACC
AUR1R tccatgtcgacgcccTTAAGCCCTC
These open reading frames were cloned into the pESC-LEU vector (Agilent) and verified by sequence anal-
yses, creating pESC-LEU_AtIPCS2 and pESC-LEU_AUR1. In this vector, expression of the open reading frame 
was under the control of a galactose-inducible promoter. All plasmids were subsequently transformed into the 
MSY23-3C S. cerevisiae strain as previously described15 and selected on SD -TRP -URA -LEU agar (0·17% Bacto 
yeast nitrogen base, 0·5% ammonium sulphate, 2% glucose, containing the appropriate nutritional supplements) 
at 30 °C. Yeast were then ‘cured’ of the pRS316-AUR1 plasmid by selection on SGR -TRP –LEU +FOA agar 
(0·17% Bacto yeast nitrogen base, 0·5% ammonium sulphate, 0.1% galactose, 1% raffinose, 0.1% 5-Fluoroorotic 
Acid Monohydrate (FOA) containing the appropriate nutritional supplements) at 30 °C, creating MSY23-3C 
pESC-LEU_AtIPCS2; and MSY23-3C pESC-LEU_AUR1. Following PCR validation and propagation in SGR 
-TRP -LEU, frozen stocks of both yeast lines were created (OD600 = 10).
When required, MSY23-3C pESC-LEU_AtIPCS2 and MSY23-3C pESC-LEU_AUR1 were thawed on ice 
and diluted 1:20 with SGR -TRP -LEU. Using a Biomek FXp automated workstation (Beckman Coulter) 198 µl 
was aliquoted into 96-well plates (Thermo Scientific) before the addition of 2 ul of compounds (to the desired 
concentration) and controls – DMSO (negative; Sigma Aldrich) and cycloheximide (to 10 µM; positive; Sigma 
Aldrich). Following incubation at 30 °C for 24 hours optical density (OD600) was measured (Biotek Synergy H4 
with Gen5™). All assays were carried out in duplicate and inhibition (%) calculated.
Secondary screening, biochemical assay. Microsomal material was prepared from MSY23-3C 
pESC-LEU_AtIPCS2 and MSY23-3C pESC-LEU_AUR1 as previously described33. IPCS turnover was assayed 
using HPTLC (Merck) and imaged using a Fuji FLA−3000 reader and AIDA Image Analyser® software (ver-
sion 3.52) as previously described17. Subsequently, a 96-well plate assay was formatted based on the protocol 
described by Mina et al.17. Following optimisation of substrate concentration and incubation time, each com-
pound at the desired concentration (100 µM to 46 nM; in triplicate), was incubated in 96-well plates (Corning® 
Costar®) in phosphate buffer (71.4 mM, pH 7.0) with soybean PI (100 µM, final concentration, Avanti), 
NBD-C6-phytoceramide (15 µM; ThermoFisher) and microsomal membranes (0.3–0.4 Units17). Following incu-
bation for 60 minutes (or 40 minutes for MSY23-3C pESC-LEU_AUR1 membranes) at 30 °C the reaction was 
quenched by the addition of 200 µl methanol per well, the reaction product separated using exchange chromatog-
raphy in 96-well filter plates (Millipore)17 and the fluorescence measured at Ex460/Em540 using a fluorescence 
Microplate Reader (Biotek Synergy H4 with Gen5™). Analyses were carried out using GraphPad Prism 7.
In vivo screening, Arabidopsis seedlings. A. thaliana (Col0) seedlings were grown for 10 days on 0.8% 
Murashige and Skoog (MS) agar and then transferred to 1.2% MS agar containing compounds at the desired 
concentrations or DMSO as a control. Plants were grown at 20 °C under 16 hour day/8 hour night photoperiod.
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